Products for Research Use Only
RegisterLogin

Aurantiamide

CAT: 0804-HY-N2909-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N2909-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models[1][2][3][4][5].
CAS Number
58115-31-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Mixed Lineage Kinase; NF-κB; RIP kinase
Type
Natural Products
Related Pathways
Apoptosis; MAPK/ERK Pathway; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/aurantiamide.html
Purity
99.56
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N[C@H](CO)CC1=CC=CC=C1)[C@@H](NC(C2=CC=CC=C2)=O)CC3=CC=CC=C3
Molecular Formula
C25H26N2O3
Molecular Weight
402.49
Precautions
H302, H315, H319
References & Citations
[1]He RB, et al. Aurantiamide mitigates acute kidney injury by suppressing renal necroptosis and inflammation via GRPR-dependent mechanism.|[2]Shen H, et al. Aurantiamide suppresses the activation of NLRP3 inflammasome to improve the cognitive function and central inflammation in mice with Alzheimer's disease. CNS Neurosci Ther. 2023 Apr;29 (4) :1075-1085.|[3]Shen H, et al. Aurantiamide promotes M2 polarization of microglial cells to improve the cognitive ability of mice with Alzheimer's disease. Phytother Res. 2023 Jan;37 (1) :101-110.|[4]Aslan M, et al. Effects of aurantiamide on a rat model of renovascular arterial hypertension. Pflugers Arch. 2023 Oct;475 (10) :1177-1192.|[5]Lijiang Chen, et al. Pharmacokinetics and Biodistribution of Aurantiamide and Aurantiamide Acetate in Rats After Oral Administration of Portulaca Oleracea L. Extracts. J Agric Food Chem. 2016 May 4;64 (17) :3445-55.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Isoform
NF-κB; RIPK3

Alternative Products

CatalogName
MBS3610455-01Aurantiamide
T125778-01Aurantiamide benzoate
AB2305Aurantiamide acetate

Popular Products